newsfilter
← Latest News
Business Wire·

Alpha Cognition to Participate in Upcoming Investor Events

  • Alpha Cognition Inc. announced that CEO Michael McFadden & COO Lauren D'Angelo will attend two upcoming investor events.
  • The company will participate in one-on-one meetings at the Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2026.
  • A fireside chat is scheduled for the Stonegate CEO Series on Thursday, December 10, 2026, at 12pm EST.
  • Alpha Cognition is a commercial-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders like Alzheimer's disease & Cognitive Impairment with mild Traumatic Brain Injury (mTBI).
  • ZUNVEYL is a patented, new generation acetylcholinesterase inhibitor approved for Alzheimer's disease that binds to alpha-7 neuronal nicotinic receptors & has minimal gastrointestinal side effects.
  • ALPHA-1062 is under development in combination with memantine for moderate to severe Alzheimer's dementia & as an intranasal formulation for mTBI.